Assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC).
A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC).
|Eligibility criteria|| |
|Study details|| |
The treatment involves immunotherapy plus chemotherapy plus radiotherapy vs the standard of care, chemotherapy with radiotherapy. While on treatment there will be regular blood tests, urine tests, cystoscopies, and scans to monitor progress. At completion of treatment the study will continue to follow your progress.
|Further information|| |
For more information regarding this clinical trial click here.
North Shore NSW